<DOC>
	<DOCNO>NCT00525707</DOCNO>
	<brief_summary>The randomized patient acute heart failure stratify base presence absence Swan-Ganz catheter assign receive either tezosentan 5 mg/h first 30 minute 1 mg/h thereafter match placebo 1:1 manner . The duration treatment 24 hour 72 hour . The duration follow-up period 30 day treatment initiation death , re-hospitalizations SAEs follow follow-up period 5 month vital status .</brief_summary>
	<brief_title>Tezosentan Acute Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>1 . Patients 18 year age old . 2 . Male nonbreastfeeding , nonpregnant female ( females post menopausal , surgically sterile practice reliable method contraception ) . 3 . Acute heart failure ( ischemic nonischemic ) . 4 . Randomization within 24 hour hospitalization ( include emergency room stay ) acute heart failure . 5 . Dyspnea rest assess patient breathing rate ³ 24/min ( measure 60 second ) . 6 . At least two follow four criterion : · elevate BNP N terminal proBNP ( three time upper limit normal site ) patient treat nesiritide , · clinical evidence pulmonary congestion/edema ( e.g. , rales crackle third base ) , · evidence pulmonary congestion chest Xray , · leave ventricular systolic dysfunction ( EF &lt; 40 % wall motion index £ 1.2 within 12 month prior randomization ) . 7 . Patients need i.v . therapy acute heart failure receive least one dose i.v . diuretic within 24 hour prior study drug initiation ( last bolus dose must 2 hour prior study drug initiation ) . 8 . Written informed consent . Criteria patient hemodynamically monitor : 1 . Baseline cardiac index &gt; 2.5 l/min/m2 and/or PCWP &lt; 20 mmHg within 6 hour prior study drug initiation . Criteria patient : 2 . Patients receive i.v . vasodilator ( e.g. , nitrate , nitroprusside , nesiritide ) baseline : supine systolic blood pressure &lt; 100 mmHg . Patients receive i.v . vasodilator ( e.g. , nitrate , nitroprusside , nesiritide ) baseline : supine systolic blood pressure &lt; 120 mmHg . 3 . Cardiogenic shock within last 48 hour evidence volume depletion . 4 . Ongoing myocardial ischaemia , coronary revascularisation procedure ( PCI CABG ) current admission plan revascularisation . 5 . STsegment elevation myocardial infarction administration thrombolytic therapy . 6 . Baseline creatinine ≥ 2.5 mg/dl ( 221 mmol/l ) . 7 . Baseline hemoglobin &lt; 10 g/dl hematocrit &lt; 30 % . 8 . Hemodialysis , ultrafiltration peritoneal dialysis within last 7 day . 9 . Heart failure due active myocarditis , obstructive hypertrophic cardiomyopathy , congenital heart disease , restrictive cardiomyopathy constrictive pericarditis . Heart failure cause valvular disease . 10 . Acute heart failure associate uncontrolled hemodynamically relevant atrial fibrillation/flutter ventricular rhythm disturbance . 11 . Acute heart failure secondary clinical evidence digoxin toxicity drugrelated toxicity . 12 . Significant chronic and/or acute lung disease might interfere ability interpret dyspnea assessment hemodynamic measurement ( e.g. , severe chronic obstructive pulmonary disease acute pneumonia ) . 13 . Mechanical circulatory ventilatory support . Prior CPAP use allow , discontinue least 2 hour prior study drug initiation . 14 . Acute systemic infection/sepsis illness life expectancy le 30 day . 15 . Coronary artery bypass graft , cardiac surgery , major noncardiac surgery within last 30 day . 16 . Patients receive another investigational drug within 30 day prior randomization . 17 . Rerandomization current study . 18 . Any factor might interfere study conduct interpretation result know drug alcohol dependence . 19 . Concomitant treatment cyclosporin A tacrolimus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>acute heart failure</keyword>
	<keyword>Actelion</keyword>
	<keyword>tezosentan</keyword>
	<keyword>acute decompensation chronic heart failure</keyword>
	<keyword>New onset heart failure</keyword>
</DOC>